Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00947908
Recruitment Status : Unknown
Verified July 2009 by University of Rostock.
Recruitment status was:  Active, not recruiting
First Posted : July 28, 2009
Last Update Posted : January 13, 2010
Sponsor:
Information provided by:
University of Rostock

Brief Summary:
Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.

Condition or disease Intervention/treatment Phase
Hymenoptera Venom Allergy Biological: Hymenoptera venom Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy
Study Start Date : June 2009
Estimated Primary Completion Date : June 2010
Estimated Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: A
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Biological: Hymenoptera venom
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).




Primary Outcome Measures :
  1. Number of myeloid DC and plasmacytoid DC in peripheral blood [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ]

Secondary Outcome Measures :
  1. Surface molecule expression on myeloid DC and plasmacytoid DC [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with diagnosed hymenoptera venom allergy
  • No previous treatments for hymenoptera venom allergy

Exclusion Criteria:

  • Treatment with immunosuppressive agents
  • Any malignant disease
  • Infections within 1 week prior to the initiation of the treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00947908


Locations
Layout table for location information
Germany
University of Rostock
Rostock, mecklenburg-Vorpommern, Germany, 18057
Sponsors and Collaborators
University of Rostock
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PD Dr. Marek Lommatzsch, University of Rostock
ClinicalTrials.gov Identifier: NCT00947908    
Other Study ID Numbers: LO-0004
First Posted: July 28, 2009    Key Record Dates
Last Update Posted: January 13, 2010
Last Verified: July 2009
Keywords provided by University of Rostock:
Hymenoptera venom allergy
Dendritic cells (DC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Immune System Diseases